Efficacy and safety of triple drug fixed-dose combination of Telmisartan, Amlodipine and Hydrochlorothiazide in the management of hypertension

ABSTRACT

Hypertension is a major health problem in India. Different clinical studies have reported that reducing the blood pressure can substantially decrease cardiovascular risk and all cause mortality. This study was conducted to evaluate the efficacy and safety of triple drug fixed dose combination of Telmisartan 40 mg, Amlodipine 5 mg and Hydrochlorthiazide 12.5mg. 41 hypertensive patients having systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥100 mmHg who were uncontrolled on dual drug therapy with Telmisartan-Amlodipine or Telmisartan-Hydrochlorothiazide combinations were enrolled in this study. The treatment period was of 120 days and patients were administered once daily fixed dose combination of Telmisartan 40 mg, Amlodipine 5 mg and Hydrochlorthiazide 12.5mg. Patients were evaluated on 15th, 30th, 60th and 120th days of treatment. There was statistically significant (p60 years and <60 years achieved the JNC VIII recommended target goal respectively. This triple drug fixed dose combination of Telmisartan, Amlodipine and hydrochlorothiazide was found to be effective and safe option for the optimal management of hypertension without any safety concern.